E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Pneumococcal vaccine responses in ANCA associated vasculitis |
|
E.1.1.1 | Medical condition in easily understood language |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Immune System Diseases [C20] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 20.1 |
E.1.2 | Level | PT |
E.1.2 | Classification code | 10050894 |
E.1.2 | Term | Anti-neutrophil cytoplasmic antibody positive vasculitis |
E.1.2 | System Organ Class | 10021428 - Immune system disorders |
|
E.1.3 | Condition being studied is a rare disease | Yes |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
Does rituximab (a newer drug, which depletes B cells (a type of cell of the immune system which is important in fighting infections and responding to vaccines), and is increasingly being used to treat patients with AAV) impair the immune system, meaning that patients do not respond to vaccines as well as patients treated with other agents and suffer more infections?
|
|
E.2.2 | Secondary objectives of the trial |
Does how well an individual responds to the vaccine depend on the number of B cells (a type of cell of the immune system which is important in fighting infections and responding to vaccines) that have returned following rituximab treatment?
As less than 1 in 5 patients are predicted to respond to one dose of pneumococcal vaccine, is it possible to boost the response by administering a further dose 6 months after the initial vaccination?
|
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
To be included in the trial all participants must: • Have given written informed consent to participate • Be aged 40 years and over
For patients in Group 1 only (rituximab treated):
• Have a diagnosis of AAV [granulomatosis with polyangiitis (GPA) or microscopic polyangiitis (MPA) or eosinophilic granulomatosis with polyangiitis (eGPA)] • Have current or historical PR3/MPO ANCA positivity by ELISA or histological confirmation of AAV • Have received ≥ 2g rituximab • Have received their last dose of rituximab at least 12 months prior to enrolment • Be in stable remission with a prednisolone dose of ≤ 5mg/day
For patients in Group 2 only (disease controls who have never received rituximab):
• Have a diagnosis of AAV (GPA, MPA or eGPA) • Have current or historical PR3/MPO ANCA positivity by ELISA or histological confirmation of AAV • Have received cyclophosphamide (oral or IV) as initial induction therapy • Be on stable immunosuppression for the 6 months preceding screening including prednisolone ≤ 5mg/day AND either azathioprine, methotrexate or mycophenolate mofetil (at stable or tapering dose)
|
|
E.4 | Principal exclusion criteria |
The presence of any of the following will preclude participant inclusion:
• Age < 40 years • History of severe allergic or anaphylactic reactions to pneumococcal vaccinations including excipients and diptheria toxoid. • Pneumococcal vaccination within 5 years prior to screening • Females who are pregnant, plan to become pregnant, or breast feeding • Medical, psychiatric, cognitive or other conditions that, in the investigator's opinion, compromise the patient's ability to understand the patient information, give informed consent, comply with the trial protocol, or to complete the study. • History of malignancy within the past five years or any evidence of persistent malignancy, except fully excised basal cell or squamous cell carcinomas of the skin, or cervical carcinoma in situ which has been treated or excised in a curative procedure. • Replacement immunoglobulin (IVIg) administered intravenously or subcutaneously in the 12 weeks prior to screening visit.
For patients in Groups 1 and 2 only (AAV patients):
• Presence of another multisystem autoimmune rheumatic disease • The prior receipt of more than 36g of cumulative cyclophosphamide ever (either IV or oral)
For patients in group 1 only (rituximab group)
• The receipt of any immune suppressing agent (azathioprine, methotrexate or mycophenolate mofetil) after rituximab
For patients in Group 2 only (disease controls):
• A relapse of AAV within the 6 months prior to screening which has necessitated an increase in prednisolone or azathioprine, methotrexate or MMF dose. • Previous rituximab therapy at any time
For healthy controls:
• Any history of any autoimmune condition • Any history of use of immune suppressing medication, including > 4 weeks of oral glucocorticoids, within the 5 years prior to screening.
|
|
E.5 End points |
E.5.1 | Primary end point(s) |
The primary outcome will compare the proportions of rituximab treated patients to disease controls who respond to the conjugated pneumococcal vaccine. Response is defined as at least a twofold increase in immunoglobulins titres in at least 6/13 of the pneumococcal serotypes tested. |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
The primary endpoint will be measured at 28 (+/- 7) days after administration of the pneumococcal polysaccharide conjugate vaccine. |
|
E.5.2 | Secondary end point(s) |
In view of the lack of validation of any primary endpoint defining response to pneumococcal vaccination, the secondary outcome measures in this study are extremely important. 1. Immunoglobulin (IgG) titres for each individual serotype in the pneumococcal vaccine will be measured at month 0, 1, 6 and 7 in all participants. 2. PBMC extraction and immunophenotyping of circulating B cell sub-populations (CD27+ memory cells CD19+ B cells and CD27-/ CD19+ naïve B cells) and T cell sub-populations. 3. Number of serious adverse events, and serious adverse events specifically related to the vaccines administered (serious adverse reactions) 4. Incidence, type, severity and treatment of infections experienced by participants after vaccinations 5. Changes in immunoglobulin levels will be measured over time
|
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
Immunoglobulin titres for each individual serotype in the pneumococcal vaccines will be performed at month 0, 1, 6 and 7.
B and T cell immunophenotyping will be performed in a subset of patients and month 0,1,6 and 7.
All severe adverse events, infections and adverse events specifically related to the vaccines administered will be collected until a subject's participation in the trial is completed at 7 months.
|
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | Yes |
E.6.3 | Therapy | No |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | Yes |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | No |
E.8.1.1 | Randomised | No |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | No |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 2 |
E.8.5 | The trial involves multiple Member States | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 2 |
E.8.9.1 | In the Member State concerned months | 7 |
E.8.9.1 | In the Member State concerned days | 1 |
E.8.9.2 | In all countries concerned by the trial years | 2 |
E.8.9.2 | In all countries concerned by the trial months | 7 |
E.8.9.2 | In all countries concerned by the trial days | 1 |